6533b827fe1ef96bd1287204

RESEARCH PRODUCT

Circulating leukocyte telomere length and oxidative stress: A new target for statin therapy

Catherine Vergely Sebastien SaliquesLuc LorgisJulie LorinSylviane RagotAnne-cécile LagrostClaude TouzeryAnne DonzelMichel FarnierPierre SicardJean-raymond TeyssierYves CottinLuc RochetteJuliane BerchoudMarianne Zeller

subject

OncologyMaleMyocardial Infarction030204 cardiovascular system & hematologymedicine.disease_causeDNA Glycosylases0302 clinical medicineRisk FactorsLeukocytesMyocardial infarctionComputingMilieux_MISCELLANEOUSAged 80 and over0303 health sciencesReverse Transcriptase Polymerase Chain ReactionConfoundingMiddle AgedTelomere3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemReal-time polymerase chain reactionOsteosarcomaFemalemedicine.symptomCardiology and Cardiovascular MedicineProto-Oncogene Proteins c-fosGenetic Markersmedicine.medical_specialtyStatinmedicine.drug_classInflammationReal-Time Polymerase Chain ReactionRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansRNA MessengerPropensity Score030304 developmental biologyAgedDyslipidemiasChi-Square Distributionbusiness.industrystatinoxidative stress 2medicine.diseaseLeukocyte telomere lengthSurgeryOxidative StressLogistic ModelsinflammationLinear ModelsHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessChi-squared distributionOxidative stress

description

International audience; Objectives: We investigated the relationship between prior statin therapy and leukocyte telomere length (LTL), as well as their interaction with potential new biomarkers of oxidative deoxyribonucleic acid (DNA) lesions and reactive oxygen species-induced inflammation.Methods and results: From patients admitted for an acute myocardial infarction, LTL was assessed by quantitative polymerase chain reaction (Q-PCR), and leukocyte Finkel-Biskis-Jinkins osteosarcoma (FOS) and 8-oxoguanine DNA glycosylase (OGG1) messenger ribonucleic acid (mRNA) levels were measured by retrotranscription Q-PCR. Patients under prior chronic statin therapy were compared with patients without statin therapy. Although patients on statin therapy were older, their mean LTL was longer than patients not under statin therapy (1.29 ± 0.11 vs. 1.25 ± 0.11 T/S ratio, p = 0.008). In contrast, FOS and OGG1 mRNA levels were similar for the 2 groups. LTL decreased with increasing age, FOS, and OGG1 mRNA levels. Statin therapy remained associated with longer LTL, even after adjustment for confounding factors (p = 0.001), and in younger patients (≤ 64 y). Even in groups matched for propensity scores for statin use, LTL was markedly longer in patients under statin therapy.Conclusions: Our observational study showed that statin therapy was associated with longer LTL. These data bring to light opportunities to identify new targets for early primary preventive treatment strategies. Moreover, our study raised FOS and OGG1 as new relevant biomarkers of LTL.

10.1016/j.atherosclerosis.2011.09.011https://hal-univ-bourgogne.archives-ouvertes.fr/hal-03435307